<DOC>
	<DOCNO>NCT00079157</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Giving vaccine Montanide ISA-51 sargramostim may cause strong immune response kill tumor cell . PURPOSE : This phase I trial study side effect best dose vaccine therapy give together Montanide ISA-51 sargramostim treat patient stage IV breast cancer .</brief_summary>
	<brief_title>Vaccine Plus Montanide ISA-51 Sargramostim Treating Patients With Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety telomerase : 540-548 peptide vaccine emulsify Montanide ISA-51 sargramostim ( GM-CSF ) patient HLA-A2-expressing stage IV breast cancer . Secondary - Compare generation human telomerase reverse transcriptase ( hTERT ) peptide-specific vs cytomegalovirus peptide-specific cytotoxic T-lymphocyte ( CTL ) immunity patient treated regimen . - Correlate dose level regimen generation hTERT-specific CTL immunity development hTERT-specific autoimmunity patient . - Determine tumor response patient treat regimen . OUTLINE : This dose-escalation study telomerase : 540-548 peptide CMV 495 peptide portion vaccine . Patients receive telomerase : 540-548 peptide CMV 495 peptide ( immunological control ) vaccine emulsify Montanide ISA-51 subcutaneously ( SC ) follow sargramostim ( GM-CSF ) SC day 1 week 1 , 3 , 5 , 7 , 11 , 15 , 19 , 27 ( total 8 vaccination ) . Treatment continue absence disease progression unacceptable toxicity . Cohorts 5-8 patient receive escalate dos telomerase : 540-548 peptide CMV 495 peptide maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 5 2 8 patient experience dose-limiting toxicity . A total 12 patient receive treatment MTD . Patients follow within 30 day 6 12 month . PROJECTED ACCRUAL : A total 5-28 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund 's Adjuvant</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage IV breast cancer Failed least 1 prior conventional therapy metastatic disease Measurable evaluable disease clinical , radiographic , laboratory assessment Measurable lesion must least 1 dimension At least 20 mm conventional technique OR least 10 mm spiral CT scan The following consider measurable : Pleural effusion Bone lesion Tumor marker HLAA2expressing disease human leukocyte antigen type No CNS metastases contrast CT scan and/or MRI No brain metastasis within past 4 year Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Not specify Menopausal status Not specify Performance status ECOG 01 Life expectancy More 6 month Hematopoietic WBC ≥ 3,000/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 10 g/dL Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN Hepatitis B negative Hepatitis C negative Renal Creatinine ≤ 1.5 time ULN Immunologic HIV negative Human Tcell lymphotrophic virus1 negative No active infection No major autoimmune disorder would preclude study participation Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study participation No alcohol abuse illicit drug use within past 12 month No clinically significant comorbid disease underlying condition would preclude study participation No significant psychiatric disorder would preclude give informed consent comply study PRIOR CONCURRENT THERAPY : Biologic therapy No prior allogeneic autologous bone marrow stem cell transplantation More 30 day since prior hematopoietic growth factor More 30 day since initiation prior immunotherapy ( e.g. , trastuzumab [ Herceptin ] ) Concurrent immunotherapy ( e.g. , trastuzumab ) allow provide regimen initiate 30 day study entry , disease stable progressive , patient plan continue immunotherapy duration study participation No concurrent hematopoietic growth factor Chemotherapy More 30 day since prior chemotherapy No concurrent chemotherapy Endocrine therapy More 30 day since prior glucocorticoid More 30 day since initiation prior hormonal therapy ( e.g. , tamoxifen , anastrozole , letrozole ) Concurrent hormonal therapy ( e.g. , tamoxifen , anastrozole , letrozole ) allow provide regimen initiate 30 day study entry , disease stable progressive , patient plan continue hormonal therapy duration study participation No concurrent glucocorticoid Radiotherapy More 30 day since prior radiotherapy No concurrent radiotherapy Surgery Not specify Other More 14 day since prior anticoagulant ( e.g. , warfarin , heparin , enoxaparin ) Lowdose anticoagulant maintain IV catheter patency allow More 30 day since prior immunosuppressive drug More 30 day since prior experimental therapy No concurrent immunosuppressive drug No concurrent investigational product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>